Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;123(Suppl 1):3-9.
doi: 10.1038/s41416-020-01069-z.

The current treatment landscape in the UK for stage III NSCLC

Matthew Evison  1 ; AstraZeneca UK Limited
Affiliations
Review

The current treatment landscape in the UK for stage III NSCLC

Matthew Evison et al. Br J Cancer. 2020 Dec.

Abstract

For stage III non-small cell lung cancer (NSCLC), approximately a third of patients survive up to 5 years, with decreasing 5-year survival rates for stage IIIB and stage IIIC disease. Although curable, stage III NSCLC encompasses a diverse range of disease presentation, with an equally complex range of multi-modal treatment options, including systemic and local therapies for distant and local disease control, respectively. This complexity results in a number of challenges for the multi-disciplinary team (MDT) in achieving optimal treatment outcomes for patients. As multi-modality treatment is the preferred treatment strategy for all stage III disease, the focus of this article is the key surgical, chemotherapy and radiotherapy clinical trials as well as guidelines that currently outline radical therapy options for patients with both potentially resectable and unresectable stage III NSCLC.

PubMed Disclaimer

Conflict of interest statement

M.E. has attended advisory boards for AMBU, AstraZeneca and Abbvie; has received honoraria from MSD, Pfizer and AstraZeneca and has received speaker fees from MSD. The author does not report any conflict of interest with regards to the contents of this study other than those stated.

Figures

Fig. 1
Fig. 1. 2017 treatment of stage IIIA and IIIB NSCLC in the UK.
This figure was created by the author from data published in the UK NLCA annual report 2018. adj adjuvant, BSC best supportive care, chemo chemotherapy, PI palliative intent, RT radiotherapy.
See this image and copyright information in PMC

References

    1. Horinouchi H. Role of multimodality therapy in cIIIA-N2 non–small cell lung cancer: perspective. Jpn. J. Clin. Oncol. 2016;46:1174–1178. - PMC - PubMed
    1. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 2015;10:990–1003. doi: 10.1097/JTO.0000000000000559. - DOI - PubMed
    1. Asamura H, Chansky K, Crowley J, Goldstraw P, Rusch V, Vansteenkiste J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 2015;10:1675–1684. doi: 10.1097/JTO.0000000000000678. - DOI - PubMed
    1. Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Tae Kim Y, Turrisi A, et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J. Thorac. Oncol. 2015;10:1515–1522. doi: 10.1097/JTO.0000000000000673. - DOI - PubMed
    1. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 2016;11:39–51. doi: 10.1016/j.jtho.2015.09.009. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources